Cases That Test Your Skills

The woman who couldn’t stop eating

Author and Disclosure Information

 

References

TREATMENT Combination therapy

Ms. C is ambivalent about her BED diagnosis, and becomes angry about it when the proposed treatments do not involve bariatric surgery or cosmetic procedures. Ms. C is enrolled in weekly individual psychotherapy, where she receives a combination of CBT and psychodynamic therapy; however, her attendance is inconsistent. Ms. C is offered a trial of fluoxetine, but adamantly refuses, citing a relative who experienced adverse effects while receiving this type of antidepressant. Ms. C also refuses a trial of topiramate due to concerns of feeling sedated. Finally, she is offered a trial of lisdexamfetamine, 30 mg/d, which was FDA-approved in 2015 to treat moderate to severe BED. We discuss the risks, benefits, and adverse effects of lisdexamfetamine with Ms. C; however, she is hesitant to start this medication and expresses increasing interest in obtaining a consultation for bariatric surgery. Ms. C is provided with extensive education about the risks and dangers of surgery before addressing her eating patterns, and the clinician provides validation, verbal support, and counseling. Ms. C eventually agrees to a trial of lisdexamfetamine, but her insurance denies coverage of this medication.

The authors’ observations

When developing an individualized treatment plan for a patient with BED, the patient’s psychiatric and medical comorbidities should be considered. Treatment goals for patients with BED include:

  • abstinence from binge eating
  • sustainable weight loss and metabolic health
  • reduction in symptoms associated with comorbid conditions
  • improvement in self-esteem and overall quality of life.

A 2015 comparative effectiveness review of management and outcomes for patients with BED evaluated pharmacologic, psychologic, behavioral, and combined approaches for treating patients with BED.7 The results suggested that second-generation antidepressants, topiramate, and lisdexamfetamine were superior to placebo in reducing binge-eating episodes and achieving abstinence from binge-eating. Weight reduction was also achieved with topiramate and lisdexamfetamine, and antidepressants helped relieve symptoms of comorbid depression.

Various formats of CBT, including therapist-led and guided self-help, were also superior to placebo in reducing the frequency of binge-eating and promoting abstinence; however, they were generally not effective in treating depression or reducing patients’ weight.7

OUTCOME Fixated on surgery

We appeal the decision of Ms. C’s insurance company; however, during the appeals process, Ms. C becomes increasingly irritable and informs us that she has changed her mind and, with the reported support of her medical doctors, wishes to undergo bariatric surgery. Although we made multiple attempts to engage Ms. C in further treatment, she is lost to follow-up.

Continue to: Bottom Line

Pages

Recommended Reading

VIDEO: Move beyond BMI to see obesity as a disease
MDedge Psychiatry
How to handle anorexia in community hospitals
MDedge Psychiatry
Interacting with horses helps veterans with PTSD; Identical twin battles anorexia
MDedge Psychiatry
Bariatric surgery ups risk of suicide, self-harm
MDedge Psychiatry
Family estrangement: Would mutual respect make a difference?
MDedge Psychiatry
FDA accepts dasotraline NDA for binge-eating disorder
MDedge Psychiatry
Study: Half of college women exhibited binge eating symptoms
MDedge Psychiatry
Yale-Brown Obsessive Scale shows value for assessing binge eating patients
MDedge Psychiatry
Duloxetine ‘sprinkle’ launches for patients with difficulty swallowing
MDedge Psychiatry
Eating disorders may add to poor type 2 control, but BMI confounds the issue
MDedge Psychiatry